AstraZeneca's cancer drug fails to meet main goal in COVID-19 trials
The drugmaker called the results from the study disappointing but said it remained committed to its clinical trials for its COVID-19 vaccine, developed in partnership with Oxford University, and its long-acting antibody combination.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Biotechnology | Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | COVID-19 | Oxford University | Partnerships | Pharmaceuticals | Study | Vaccines